Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

21.61 +0.31 (+1.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs. 
Via Benzinga
News headline image
Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗
Roivant (ROIV) Q2 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Looking Into Roivant Sciences Ltd's Recent Short Interest ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Roivant Sciences ↗
 
Via Benzinga
News headline image
A Glimpse of Roivant Sciences's Earnings Potential ↗
 
Via Benzinga
News headline image
What Does the Market Think About Roivant Sciences? ↗
 
Via Benzinga
News headline image
6 Analysts Assess Roivant Sciences: What You Need To Know ↗
 
Via Benzinga
News headline image
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,... 
Via Stocktwits
News headline image
Why Roivant Sciences Stock Is Soaring Today ↗
The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug. 
Via The Motley Fool
News headline image
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results. 
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Peering Into Roivant Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Roivant Sciences's Earnings Outlook ↗
 
Via Benzinga
News headline image
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗
The company is working on a treatment for an autoimmune disease that affects the skin and muscles. 
Via Investor's Business Daily
News headline image
Why Roivant Sciences Stock Bounced Back on Tuesday ↗
Investors were in a forgiving mood after Monday's dispiriting earnings release. 
Via The Motley Fool
News headline image
Why Roivant Sciences Stock Was Slipping on Monday ↗
The distinctive biotech wasn't a sector favorite as the trading week began. 
Via The Motley Fool
News headline image
Roivant Sciences Q3 Earnings Assessment ↗
 
Via Benzinga
News headline image
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings.... 
Via MarketMinute
Topics Economy Stocks
News headline image
Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday? ↗
Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of... 
Via Benzinga
Topics Government
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 29, 2025 ↗
 
Via Benzinga
News headline image
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗
The company is getting a new chief executive and a new chief financial officer amid sweeping changes. 
Via Investor's Business Daily
Topics Government
News headline image
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402. 
Via Benzinga
News headline image
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗
The companies reported positive results for their lead asset in patients with two rare diseases. 
Via Investor's Business Daily
News headline image
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday? ↗
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while... 
Via Benzinga
Topics Government World Trade
News headline image
Roivant Sciences Tops Q3 Expectations ↗
Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline. 
Via The Motley Fool
News headline image
Earnings Scheduled For February 10, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.